• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Vistagen Therapeutics Inc (NQ: VTGN )

    3.080 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Vistagen Therapeutics Inc

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    11 12 Next >
    Earnings Scheduled For August 10, 2023
    Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million. 
    Via Benzinga
    What's Going On With VistaGen Therapeutics Stock?
    VistaGen Therapeutics Inc (NASDAQ: VTGN) shares are trading lower Tuesday. 
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Schedules Release of Q1 2024 Numbers, Corporate Update Conference Call
    Via Investor Brand Network
    Vistagen To Report First Quarter Financial Results and Host Corporate Update Conference Call on August 10, 2023
    From Vistagen
    Via Business Wire
    VistaGen Therapeutics Inc. (NASDAQ: VTGN) Near the Top of Equities by Percentage Gain on 8/7
    Via Investor Brand Network
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Why Energizer Holdings Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Gainers Nuburu, Inc. (NYSE: BURU) shares jumped 185.6% to $1.6593 after the company announced contract with NASA to demonstrate feasibility of power beaming in space using the company’s blue laser... 
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Why Is Vistagen Therapeutics (VTGN) Stock Up 650% Today?
    Vistagen Therapeutics has reported positive Phase 3 trial results for a social anxiety treatment. VTGN stock is skyrocketing as a result. 
    Via InvestorPlace
    Dow Gains 1%; Tabula Rasa HealthCare Shares Spike Higher
    U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 350 points on Monday. The Dow traded up 1.02% to 35,423.19 while the NASDAQ rose 0.24% to 13,942.57. The S&P... 
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Crude Oil Down Over 1%; Henry Schein Earnings Top Views
    U.S. stocks were higher midway through trading, with the Dow Jones gaining more than 300 points on Monday. The Dow traded up 0.88% to 35,374.41 while the NASDAQ rose 0.12% to 13,925.71. The S&P 500,... 
    Via Benzinga
    Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of... 
    Via Benzinga
    InvestorNewsBreaks – VistaGen Therapeutics Inc.’s (NASDAQ: VTGN) Fasedienol Demonstrates Potential to Transform Treatment Landscape for Social Anxiety Disorder
    Via Investor Brand Network
    Elanco Animal Health, Sovos Brands, Veritiv, Graham And Other Big Stocks Moving Higher On Monday
    U.S. stocks traded higher, with the Dow Jones gaining around 300 points on Monday. Here are some big stocks recording gains in today’s session. 
    Via Benzinga
    Dow Jumps 250 Points; Tyson Foods Posts Downbeat Results
    U.S. stocks were higher this morning, with the Dow Jones gaining more than 250 points on Monday. Following the market opening Monday, the Dow traded up 0.77% to 35,334.81 while the NASDAQ rose 0.42% to... 
    Via Benzinga
    Vistagen's Big Breakthrough: Says Single Administration Of Nasal Spray Candidate Can Potentially Reduce Anxiety Symptoms, Stock Skyrockets
    Vistagen Therapeutics Inc (NASDAQ: VTGN) released topline results from its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of fasedienol (PH94B) nasal spray in adults... 
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Vistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder
    From Vistagen
    Via Business Wire
    VistaGen's New Preclinical Depression Treatment Study: Itruvone Nasal Spray Limits Systemic Exposure, Shows Promise
    Vistagen Inc (NASDAQ: VTGN) revealed a new mechanism of action data from a preclinical tissue distribution  
    Via Benzinga
    InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces New Preclinical Data Further Demonstrating Unique Mechanism of Action for Itruvone (‘PH10’)
    Via Investor Brand Network
    Vistagen Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Spray’s Potential Antidepressant Activity via Peripheral Nasal Neurons without Entry into the Brain
    From Vistagen
    Via Business Wire
    InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Announces Receipt from CIPO of Notice of Allowance for Dyskinesia Treatment
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease
    From Vistagen
    Via Business Wire
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases FY 2023 Financial Report, Corporate Update
    Via Investor Brand Network
    Vistagen Provides Corporate Update and Reports Fiscal Year 2023 Financial Results
    From Vistagen
    Via Business Wire
    InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Scheduled Conference Call to Report on FY 2023 Financial Numbers
    Via Investor Brand Network
    Earnings Scheduled For June 28, 2023
    Companies Reporting Before The Bell • General Mills (NYSE:GIS) is estimated to report quarterly earnings at $1.07 per share on revenue of $5.17 billion. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    11 12 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.